XLON
RKT
Market cap42bUSD
Sep 17, Last price
5,006.00GBP
1D
-0.99%
1Q
8.50%
Jan 2017
-27.30%
IPO
87.75%
Name
Reckitt Benckiser Group PLC
Chart & performance
P/E
9.99
P/S
2.24
EPS
5.01
Div yield, %
4.29%
Shrs. gr., 5y
-1.74%
Rev. gr., 5y
0.30%
Revenues
14.21b
+0.25%
Net income
3.18b
+123.14%
CFO
2.30b
-14.35%
Dividend
Aug 06, 202688.6 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
Related entities
Subsidiaries (65)
RECKITT BENCKISER (BRANDS) LIMITED
RECKITT BENCKISER (CZECH REPUBLIC), SPOL. S R.O.
RECKITT BENCKISER (ENA) B.V.
RECKITT BENCKISER (GRANOLLERS) SL
RECKITT BENCKISER (LANKA) LIMITED
RECKITT BENCKISER (POLAND) SPÓŁKA AKCYJNA
RECKITT BENCKISER (ROMANIA) SRL
RECKITT BENCKISER (SLOVAK REPUBLIC), SPOL. S R.O.
RECKITT BENCKISER (SOUTH AMERICA) HOLDING B.V.
RECKITT BENCKISER AUSTRIA GMBH
RECKITT BENCKISER CORPORATE SERVICES LIMITED
RECKITT BENCKISER FRANCE SAS
RECKITT BENCKISER HEALTH LIMITED
RECKITT BENCKISER HEALTHCARE (UK) LIMITED
RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED
RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED
RECKITT BENCKISER HEALTHCARE MANUFACTURING (THAILAND) LTD.
RECKITT BENCKISER INVESTMENTS LIMITED
RECKITT BENCKISER ITALIA SPA
RECKITT BENCKISER KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG
Branches
BELEGGINGSMAATSCHAPPIJ LEMORE B.V.
Key people
Non-Executive Independent Director · since 2025
Designated Non-Executive Independent Director · since 2024
Headquarters & legal address
103-105 BATH ROAD
SLOUGH, SLG SL1 3UH
GB
SLOUGH, SLG SL1 3UH
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||